# ICMJE DISCLOSURE FORM

Date:\_\_\_5<sup>th</sup> March 2021\_\_\_\_\_ Your Name:\_Dr Samantha Quaife\_\_\_\_\_ Manuscript Title: The person behind the nodule: a narrative review of the psychological impact of lung cancer screening Manuscript number (if known): TLCR-20-1179

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial pla	Specifications/Comments (e.g., if payments were made to you or to your institution) anning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials,	None	
	medical writing, article processing charges, etc.) No time limit for this item.		
		Time frame: past 36	months
2	Grants or contracts from any entity (if not indicated	Cancer Research UK Postdoctoral Fellowship (PI)	Funding made to the institution (UCL)
	in item #1 above).	Cancer Research UK EDAG Project Grant (PI)	Funding made to the institution (UCL)
		Cancer Research UK EDAG Project Grant (Co-I)	Funding made to the institution (UCL)
		Roy Castle Lung Cancer Foundation Project Grant (PI)	Funding made to the institution (UCL)
3	Royalties or licenses	None	

4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	InHealth British Thoracic Oncology Group (BTOG) European Respiratory Society (ERS)	Travel and accommodation to attend as invited speaker at an InHealth Radiography seminar (UK) Travel and accommodation to attend as invited speaker at BTOG conference (UK) Travel and accommodation to attend as invited speaker at ERS meeting (Spain)
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non- financial interests	None	

# Please summarize the above conflict of interest in the following box:

Dr Quaife reports funding from Cancer Research UK and the Roy Castle Lung Cancer Foundation, as well as support for attending meetings from the British Thoracic Oncology Group, InHealth, and the European Respiratory Society. No conflicts relating to this work.

Please place an "X" next to the following statement to indicate your agreement:

# \_\_X\_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

# ICMJE DISCLOSURE FORM

Date:	1 <sup>th</sup> March 2021
Your Nar	ne:Sam Janes
Manuscr	ipt Title: The person behind the nodule: a narrative review of the psychological impact of lung cancer screening
Manuscr	ipt number (if known): TLCR-20-1179

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	GRAIL Inc Owlstone	Funding for the SUMMIT study Funding for LUCID2
3	Royalties or licenses	None	
4	Consulting fees	Johnson and Johnson Bard1 Lifescience Astra-Zeneca	Advisory Board Advisory Board Advisory Board

5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
	testimony		
_			
7	Support for attending meetings and/or travel	Astra Zeneca	ATS 2018 San Diego
		Takeda	WCLC 2019 Barcelona
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	DSMB	Must-ARDS trial Athersys
	Safety Monitoring Board or	DMEC	REALIST trial
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	Stock	BARD1 Lifescience
		Options	OPTELLUM
12	Pacaint of aquinment	None	
12	Receipt of equipment, materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	None	
-	financial interests		

# Please summarize the above conflict of interest in the following box:

Professor Janes reports funding from GRAIL Inc and Owlstone, consulting fees from Johnson and Johnson, Bard1 Lifescience and Astra-Zeneca, support for attending meetings from Astra-Zeneca and Takeda, participation on a Data Safety Monitoring Board for the Must-ARDS trial Athersys, participation on a DMEC for the REALIST trial, stock for BARD1 Lifescience, and options for Optellum. Prof Janes does not have any conflicts directly pertaining to this work.

Please place an "X" next to the following statement to indicate your agreement:

\_X\_\_ I certify that I have answered every question and have not altered the wording of any of the questions on this

form.

# ICMJE DISCLOSURE FORM

Date:\_\_\_5<sup>th</sup> March 2021\_\_\_\_\_ Your Name:\_Professor Kate Brain\_\_\_\_\_ Manuscript Title: The person behind the nodule: a narrative review of the psychological impact of lung cancer screening Manuscript number (if known): TLCR-20-1179

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	Welsh Government via Health and Care Research Wales	Funding for the institution (School of Medicine, Cardiff University)
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	Astra Zeneca workshop on lung cancer during COVID- 19	Personal honorarium
6	Payment for expert	None	
	testimony		
7	Support for attending meetings and/or travel	International Association for the Study of Lung Cancer	Travels to attend as Invited speaker at the World Lung Cancer Conference, Toronto 2018
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or	None	
10	Advisory Board Leadership or fiduciary role	None	
10	in other board, society, committee or advocacy group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non- financial interests	None	

#### Please summarize the above conflict of interest in the following box:

Professor Brain reports funding from the Welsh Government via Health and Care Research Wales, a personal honorarium from AstraZeneca for speaking at a workshop, and support for attending a meeting from the International Association for the Study of Lung Cancer. No conflicts relating to this work.

Please place an "X" next to the following statement to indicate your agreement:

\_\_X\_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.